Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Natalie Brunette"'
Autor:
Lilit Grigoryan, Audrey Lee, Alexandra C. Walls, Lilin Lai, Benjamin Franco, Prabhu S. Arunachalam, Yupeng Feng, Wei Luo, Abigail Vanderheiden, Katharine Floyd, Samuel Wrenn, Deleah Pettie, Marcos C. Miranda, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Robert L. Coffman, David Novack, Harry Kleanthous, Derek T. O’Hagan, Robbert van der Most, Jason S. McLellan, Mehul Suthar, David Veesler, Neil P. King, Bali Pulendran
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-14 (2022)
Abstract Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by leading adjuvant candidates. In this study, we comp
Externí odkaz:
https://doaj.org/article/2196e1d269574af6a71cb396be3fe2ca
Autor:
Daniel Ellis, Natalie Brunette, Katharine H. D. Crawford, Alexandra C. Walls, Minh N. Pham, Chengbo Chen, Karla-Luise Herpoldt, Brooke Fiala, Michael Murphy, Deleah Pettie, John C. Kraft, Keara D. Malone, Mary Jane Navarro, Cassandra Ogohara, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Maggie Ahlrichs, Max Johnson, Alyssa Blackstone, Lauren Carter, Tyler N. Starr, Allison J. Greaney, Kelly K. Lee, David Veesler, Jesse D. Bloom, Neil P. King
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The unprecedented global demand for SARS-CoV-2 vaccines has demonstrated the need for highly effective vaccine candidates that are thermostable and amenable to large-scale manufacturing. Nanoparticle immunogens presenting the receptor-binding domain
Externí odkaz:
https://doaj.org/article/ee4c16cc940d4a98bc65cf319a369f9a
Autor:
Shankar Subramaniam, David Veesler, Lauren Carter, David Novack, Claire Sydeman, Jane Fontenot, Douglas E. Ferrell, Galit Alter, Robbert van der Most, Robert L. Coffman, Elizabeth Kepl, Mary Jane Navarro, Alexander G. White, Ching-Lin Hsieh, Kenneth S. Plante, Francois Villinger, Katharina Röltgen, Prabhu S. Arunachalam, Alexandra C. Walls, Jason S. McLellan, Lisa Shirreff, Rino Rappuoli, Sally Shin, Venkata Viswanadh Edara, Jessica A. Plante, Brooke Fiala, Stephanie Fischinger, Chunfeng Li, Caroline Atyeo, Matthew J. Gorman, Chad J. Roy, Scott D. Boyd, Bali Pulendran, Kasi E. Russell-Lodrigue, Skye Spencer, Xiaoying Shen, Shakti Gupta, Derek T. O'Hagan, Pyone P. Aye, Meera Trisal, Neil P. King, JoAnne L. Flynn, Nadia A. Golden, Marcos C. Miranda, Michael E. P. Murphy, John C. Kraft, Mehul S. Suthar, Lilin Lai, Jason Dufour, Rudolph Bohm, Deleah Pettie, Lara A. Doyle-Meyers, David C. Montefiori, Christopher Monjure, Kenneth A. Rogers, Samuel Wrenn, Harry Kleanthous, Nicholas J. Maness, Jay Rappaport, Alex Lee Zhu, Natalie Brunette
Publikováno v:
Nature. 594:253-258
The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1. Here we demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442cf7639520da9f4126cb4a6dcc72fb
https://doi.org/10.1038/s41586-021-03530-2
https://doi.org/10.1038/s41586-021-03530-2
Autor:
Alexandra C. Walls, Laura A. VanBlargan, Kai Wu, Angela Choi, Mary Jane Navarro, Diana Lee, Laura Avena, Daniela Montes Berrueta, Minh N. Pham, Sayda Elbashir, Marcos C. Miranda, Elizabeth Kepl, Max Johnson, Alyssa Blackstone, Kaitlin Sprouse, Brooke Fiala, Megan A. O’Connor, Natalie Brunette, Prabhu S. Arunachalam, Lisa Shirreff, Kenneth Rogers, Lauren Carter, Deborah H. Fuller, Francois Villinger, Bali Pulendran, Michael S. Diamond, Darin K. Edwards, Neil P. King, David Veesler
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development of a large number of vaccines, several of which are now approved for use in humans. Understanding vaccine-elicited antibody responses aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b41db2620d879ef9b5d36cae1917cb60
https://doi.org/10.1101/2022.02.07.479468
https://doi.org/10.1101/2022.02.07.479468
Autor:
Charles A. Whittaker, Aiquan Chang, J. Christopher Love, Hanne Leth Andersen, Lisa H. Tostanoski, Ozan S. Kumru, Nicolas Collin, Brooke Fiala, Megan Lok, Neil P. King, Brittany L. Hartwell, Danielle L Camp, Joseph R. Brady, Mary Kate Tracey, Andrew M. Biedermann, Kristen A Rodrigues, Harry Kleanthous, Jing Yang Wang, Katherine McMahan, Judith M. Silverman, Murillo Silva, Sergio A. Rodriguez-Aponte, David B. Volkin, Darrell J. Irvine, Thomas Courant, Maciel Porto, Sangeeta B. Joshi, Jingyou Yu, Patrice M. Dubois, Swagata Kar, Dan H. Barouch, Ashley A. Lemnios, Lauren Carter, Christopher A Naranjo, Ryan S Johnston, Celia Lebas, Dongsoo Yun, Neil C. Dalvie, Carl Walkey, Natalie Brunette, Laura E. Crowell, Kerry R. Love, Kawaljit Kaur, Mark G. Lewis
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs).1 Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access.2 Subunit vac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f708622e17cebfff295c987cf72435
https://doi.org/10.1073/pnas.2106845118
https://doi.org/10.1073/pnas.2106845118
Autor:
Lilit Grigoryan, Audrey Lee, Alexandra C. Walls, Lilin Lai, Benjamin Franco, Prabhu S. Arunachalam, Yupeng Feng, Wei Luo, Abigail Vanderheiden, Katharine Floyd, Samuel Wrenn, Deleah Pettie, Marcos C. Miranda, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Robert L. Coffman, David Novack, Harry Kleanthous, Derek T. O’Hagan, Robbert van der Most, Jason S. McLellan, Mehul Suthar, David Veesler, Neil P. King, Bali Pulendran
Publikováno v:
NPJ vaccines. 7(1)
Adjuvants enhance the magnitude and the durability of the immune response to vaccines. However, there is a paucity of comparative studies on the nature of the immune responses stimulated by leading adjuvant candidates. In this study, we compared five
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97ad23ef164f6a2dd15d8232f9ae9433
https://pubmed.ncbi.nlm.nih.gov/35606518
https://pubmed.ncbi.nlm.nih.gov/35606518
Autor:
Bali Pulendran, Allison J. Greaney, Max Johnson, Brooke Fiala, Ralph S. Baric, Jesse D. Bloom, Tyler N. Starr, Elizabeth Kepl, Rashmi Ravichandran, David Veesler, Roland Tisch, Mary-Jane Navarro, Kenneth A. Rogers, Kaitlin R. Sprouse, Kelly D. Smith, Natalie Brunette, Megan A. O'Connor, M. Alejandra Tortorici, Douglas E. Ferrell, Davide Corti, Prabhu S. Arunachalam, Timothy P. Sheahan, Samuel Wrenn, Robbert van der Most, Sarah R. Leist, Lisa Shirreff, Harry Kleanthous, Marcos C. Miranda, Alyssa Blackstone, Claire Sydeman, Francois Villinger, Jason S. McLellan, Deleah Pettie, David R. Martinez, Cassandra Ogohara, Minh N. Pham, Lauren Carter, Wesley C. Van Voorhis, Deborah H. Fuller, Samantha K Zepeda, Alexandra Schäfer, Sasha W Tilles, Matthew Clark, Alexandra C. Walls, Rino Rappuoli, John E. Bowen, Neil P. King, Derek T. O'Hagan, Ching-Lin Hsieh
Publikováno v:
Cell
bioRxiv
article-version (status) pre
article-version (number) 1
bioRxiv
article-version (status) pre
article-version (number) 1
Understanding vaccine-elicited protection against SARS-CoV-2 variants and other sarbecoviruses is key for guiding public health policies. We show that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine (RBD-NP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98c5d8df56cfa58183e50431d4e430ba
https://pubmed.ncbi.nlm.nih.gov/34619077
https://pubmed.ncbi.nlm.nih.gov/34619077
Autor:
Bali Pulendran, David Novack, Deleah Pettie, Jay Rappaport, Xiaoying Shen, Ching-Lin Hsieh, Rudolph B Bohm, Alexandra C. Walls, Elizabeth Kepl, David Veesler, Shankar Subramaniam, Rino Rappuoli, Harry Kleanthous, Claire Sydeman, Derek T O Hagan, Alex Lee Zhu, JoAnne L. Flynn, Robbert van der Most, Christopher Monjure, Kenneth S. Plante, Francois Villinger, Prabhu S. Arunachalam, Nicholas J. Maness, Pyone P. Aye, Sally Shin, Matthew J. Gorman, Natalie Brunette, Michael E. P. Murphy, Lilin Lai, Scott D. Boyd, Caroline Atyeo, Katharina Röltgen, Venkata Viswanadh Edara, Robert L Coffman, Chad J. Roy, Kasi E. Russell-Lodrigue, David C. Montefiori, Nadia A. Golden, Meera Trisal, Jessica A. Plante, John C. Kraft, Mehul S. Suthar, Jason Dufour, Kenneth A. Rogers, Marcos C. Miranda, Lisa Shirreff, Brooke Fiala, Samuel Wrenn, Lara Doyle-Meyer, Shakti Gupta, Douglas E. Ferrell, Jane Fontenot, Jason S. McLellan, Lauren Carter, Mary Jane Navarro, Alexander G. White, Stephanie Fischinger, Neil P. King, Galit Alter, Chunfeng Li
Publikováno v:
bioRxiv : the preprint server for biology.
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7d21f226ab76efebd2264b0b460ab88
https://pubmed.ncbi.nlm.nih.gov/33873199
https://pubmed.ncbi.nlm.nih.gov/33873199
Autor:
Prabhu S, Arunachalam, Alexandra C, Walls, Nadia, Golden, Caroline, Atyeo, Stephanie, Fischinger, Chunfeng, Li, Pyone, Aye, Mary Jane, Navarro, Lilin, Lai, Venkata Viswanadh, Edara, Katharina, Röltgen, Kenneth, Rogers, Lisa, Shirreff, Douglas E, Ferrell, Samuel, Wrenn, Deleah, Pettie, John C, Kraft, Marcos C, Miranda, Elizabeth, Kepl, Claire, Sydeman, Natalie, Brunette, Michael, Murphy, Brooke, Fiala, Lauren, Carter, Alexander G, White, Meera, Trisal, Ching-Lin, Hsieh, Kasi, Russell-Lodrigue, Christopher, Monjure, Jason, Dufour, Skye, Spencer, Lara, Doyle-Meyers, Rudolph P, Bohm, Nicholas J, Maness, Chad, Roy, Jessica A, Plante, Kenneth S, Plante, Alex, Zhu, Matthew J, Gorman, Sally, Shin, Xiaoying, Shen, Jane, Fontenot, Shakti, Gupta, Derek T, O'Hagan, Robbert, Van Der Most, Rino, Rappuoli, Robert L, Coffman, David, Novack, Jason S, McLellan, Shankar, Subramaniam, David, Montefiori, Scott D, Boyd, JoAnne L, Flynn, Galit, Alter, Francois, Villinger, Harry, Kleanthous, Jay, Rappaport, Mehul S, Suthar, Neil P, King, David, Veesler, Bali, Pulendran
Publikováno v:
bioRxiv
The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0221be8b7aa6f9e1845cc9a754c8f22
https://pubmed.ncbi.nlm.nih.gov/33594366
https://pubmed.ncbi.nlm.nih.gov/33594366
Autor:
Sebastian Ols, Klara Lenart, Rodrigo Arcoverde Cerveira, Marcos C miranda, Natalie Brunette, Jana Kochmann, Martin Corcoran, Rebecca Skotheim, Annika Philomin, Alberto Cagigi, Brooke Fiala, Samuel Wrenn, Jessica Marcandalli, Fredrika Hellgren, Elizabeth A Thompson, Ang Lin, Florian Gegenfurtner, Azad Kumar, Man Chen, Ganesh E Phad, Barney S Graham, Laurent Perez, Andrew J Borst, Gunilla B Karlsson Hedestam, Tracy J Ruckwardt, Neil P King, Karin Loré
Nanoparticles for multivalent display and delivery of vaccine antigens have emerged as a promising avenue for enhancing B cell responses to protein subunit vaccines. Here, we evaluated B cell responses in rhesus macaques immunized with prefusion stab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e5c8c6f65335ccc060c0bcc37b3b1fb